Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: Potential targets for an efficient preventive intervention

International Journal of Environmental Research and Public Health

Volumn 11, Issue 4, 2014, Pages 3586-3598

  Lukic, Ljiljana ^a   Lalic, Nebojsa M ^a   Rajkovic, Natasa ^a   Jotic, Aleksandra ^a   Lalic, Katarina ^a   Milicic, Tanja ^a   Seferovic, Jelena P ^a   Macesic, Marija ^a   Gajovic, Jelena Stanarcic ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Hypertension; IL 6; Insulin resistance; Obesity; Prevention; Type 2 diabetes

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

BODY SIZE; DIABETES; DISEASE CONTROL; DISEASE INCIDENCE; ENZYME ACTIVITY; HEALTH STATUS; HYPERTENSION; LIFESTYLE; OBESITY; RISK ASSESSMENT;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE INSULIN SENSITIVITY INDEX; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897137864     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph110403586     Document Type: Article

References (51)

1. Savoia, C.; Schiffrin, E. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin. Sci. 2007, 112, 375-384.
2. Pearson, T. A.; Mensah, G. A.; Alexander, R. W.; Anderson, J. L.; Cannon, R. O.; Criqui, M.; Fadl, Y. Y.; Fortmann, S. P.; Hong, Y.; Myers, G. L.; et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003, 107, 499-511.
3. Hotamisligil, G. S. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 1999, 245, 621-625.
4. Febbraio, M. A.; Pedersen, B. K. Muscle derived interleukin-6: Mechanisms for activation and possible biological roles. FASEB J. 2002, 16, 1335-1347.
5. Shoelson, S. E.; Lee, J.; Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116, 1793-1801.
6. Tataranni, P. A.; Ortega, E. A burning question: Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005, 54, 917-927.
7. Carley, A. L.; Bruce, C. R.; Sacchetti, M.; Anderson, M. J.; Olsen, D. B.; Saltin, B.; Hawley, J. A.; Febbraio, M. A. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: Evidence that plasma interleukin-6 is related to fat mass not insulin responsiveness. Diabetologia 2004, 47, 1029-1037.
8. Cartier, A.; Lemieux, I.; Almeras, N.; Tremblay, A.; Bergeron, J.; Despres, J. P. Visceral obesity and plasma glucoe-insulin homeostasis: Contributions of interleukin-6 and tumor necrosis factor-alpha in men. J. Clin. Endocrinol. Metab. 2008, 93, 1931-1938.
9. McLaughlin, T.; Abbasi, F.; Lamendola, C.; Liang, L.; Reaven, G.; Schaaf, P.; Reaven, P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002, 106, 2908-2912.
10. Preik, M.; Kelm, M.; Rosen, P.; Tschope, D.; Strauer, B. Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of human forarm vasculature. Angiology 2000, 51, 545-554.
11. Natali, A.; Toschi, E.; Baldeweg, S.; Ciociaro, D.; Favilla, S.; Sacca, L.; Ferranninni, E. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006, 55, 1133-1140.
12. Al-Shukaili, A.; AL-Ghafri, S.; Al-Marhoobi, S.; Al-Abri, S.; Al-Lawati, J.; Al-Maskari, M. Analysis of inflammatory mediators in type 2 diabetes patients. Int. J. Endocrinol. 2013, 2013, doi: org/10. 1155/2013/976810.
13. Van Bussel, B. C.; Schouten, F.; Henry, R. M.; Schalkwijk, C. G.; de Boer, M. R.; Ferreira, I.; Smulders, Y. M.; Twisk, J. W.; Stehouwer, C. D. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011, 58, 588-595.
14. Garcia, C.; Feve, B.; Ferre, P.; Halimi, S.; Baizri, H.; Bordier, L.; Guiu, G.; Dupuy, O.; Bauduceau, B.; Mayaudon, H. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab. 2010, 36, 327-338.
15. Goldfine, A. B.; Fonseca, V.; Shoelson, S. E. Therapeutic approaches to target inflammation in type 2 diabetes. Clinical Chemistry 2011, 57, 162-167.
16. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of A WHO/IDF Consultation; World Health Organization: Geneva, Switzerland, 2006.
17. Chobanian, A. V.; Bakris, G. R.; Black, H. F.; Cushman, W. C.; Green, L. A.; Izzo, J. L.; Jones, D. W.; Materson, B. J.; Oparil, S.; Wright, J. T.; et al. National Heart, Lung and Blood Institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; National High Blood Pressure Education Program Coordinating Committee: Seventh report of joint national committee on prevention, detection, evaluation and treatment of high blood pressure; the JNC 7 report. J. Amer. Med. Assoc. 2003, 289, 2560-2572.
18. Mari, A.; Pacini, G.; Murphy, E.; Ludvik, B.; Nolan, J. J. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24, 539-548.
19. Messerli, F. H.; Williams, B.; Ritz, E. Essential hypertension. Lancet 2007, 370, 591-603.
20. Ferrannini, E.; Buzzigoli, G.; Bonadona, R. Insulin resistance in essential hypertension. N. Engl. J. Med. 1987, 317, 350-357.
21. Pollare, T; Lithell, H.; Berne, C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990, 39, 167-174.
22. Reaven, GM; Lithell, H; Lansberg, L. Hypertension and associated metabolic abnormalities-The role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 1996, 334, 374-381.
23. Sironi, A. M.; Gastaldelli, A.; Mari, A.; Ciociaro, D.; Postano, V.; Buzzigoli, E.; Ghione, S.; Turchi, S.; Lombardi, M.; Ferrannini, E. Visceral fat in hypertension influence on insulin resistance and β-cell function. Hypertension 2004, 44, 127-133.
24. Sironi, A. M.; Pingitore, A.; Ghione, S.; De Marchi, D.; Scattini, B.; Positano, V.; Muscelli, E.; Ciociaro, D.; Lombardi, M.; Ferrannini, E.; et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension 2008, 51, 282-288.
25. Mari, A.; Pacini, G.; Brazzale, A. R.; Ahren, B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005, 48, 748-751.
26. Tran, T. T.; Gupta, N.; Goh, T.; Naigamwalla, D.; Chia, M. C.; Koohestani, N.; Mehrotra, S.; McKeown-Eyssen, G.; Giacca, A.; Bruce, W. R. Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol. Biomark. Prev. 2003, 12, 47-56.
27. Mari, A.; Tura, A.; Pacini, G.; Kautzky-Willer, A.; Ferrannini, E. Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. Diabet. Med. 2008, 25, 671-677.
28. Bastard, J. P.; Vandernotte, J. M.; Faraj, M.; Karelis, A. D.; Messier, L.; Malita, F. M.; Garrel, D.; Prud'homme, D.; Rabasa-Lhoretet, R. Relationship between the hyperinsulinemic-euglycaemic clamp and a new simple index assessing insulin sensitivity in overweight and obese postmenopausal women. Diabetes Metab. 2007, 33, 261-268.
29. Muniyappa, R.; Lee, S.; Chen, H.; Quon, M. J. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab. 2008, 294, E15-E26.
30. Pickup, J. C.; Crook, M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41, 1241-1248.
31. Weisberg, S. P.; McCann, M.; Desai, M.; Rosenbaum, R.; Leibel, L.; Ferrante, A. W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003, 112, 1796-1808.
32. Kern, P. A.; Ranganathan, S.; Li, C.; Wood, L.; Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E745-E751.
33. Stephens, J. W.; Hurel, S. J.; Cooper, J. A.; Acharya, J.; Miller, G. J.; Humphries, S. E. A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. Mol. Genet. Metab. 2004, 82, 180-186.
34. Olson, C. N.; Callas, W. P.; Hanley, A. J.; Festa, A.; Haffner, S. M.; Wagenknecht, L. E.; Tracy, R. P. Circulating levels of TNF are associated with impaired glucose tolerance, increased insulin reistance, and ethinicity: The insulin resistance atherosclerosis study. J. Clin. Endocrinol. Metab. 2012, 97, 1032-1040.
35. Zinman, B.; Hanley, A. J.; Harris, S. B.; Kwan, J.; Fantus, I. G. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 1999, 84, 272-278.
36. Miyazaki, Y.; Pipek, R.; Mandarino, L. J.; DeFronzo, R. A. Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int. J. Obes. 2003, 27, 88-94.
37. Popko, E.; Gorska, A.; Stelmaszczyk-Emmel, A.; Plywaczewski, R.; Stoklosa, A.; Gorecka, D.; Pyrzak, B.; Demkow, U. Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects. Eur. J. Med. Res. 2010, 15, 120-122.
38. Hu, F. B.; Meigs, J. B.; Li, T. Y.; Manson, J. E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53, 693-700.
39. Schmidt, M. I.; Duncan, B. B.; Sharrett, A. R. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): A cohort study. The Lancet 1999, 353, 1649-1652.
40. Boos, C. J.; Lip, G. Y. H. Is hypertension an inflammatory process? Curr. Pharm. Des. 2006, 12, 1623-1635.
41. Pérez Pérez, A.; Ybarra Muñoz, J.; Blay Cortés, V; De Pablos Velasco, P. Obesity and cardiovascular disease. Public Health Nutr. 2007, 10, 1156-1163.
42. De Jager, J.; Dekker, J. M.; Kooy, A.; Kostense, P. J.; Nijpels, G.; Heine, R. J.; Bouter, L. M.; Stehouwer, C. D. A. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes The Hoorn Study. Arterioscler. Thromb. Vasc. Boil. 2006, 26, 1086-1093.
43. Ganne, S.; Arora, S. K.; Dotsenko, O.; McFarlane, S. I.; Whaley-Connell, A. Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. Curr. Diabetes Rep. 2007, 7, 208-217.
44. Pirro, M.; Schillaci, G.; Savarese, G.; Gemelli, F.; Mannarino, M. R.; Siepi, D.; Bagaglia, F.; Mannarino, E. Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11, 497-502.
45. Egan, B. M. Insulin resistance and sympathetic nervous system. Curr. Hypertens. Rep. 2003, 5, 247-254.
46. Frontoni, S.; Bracaglia, D.; Gigli, F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 441-449.
47. Olson, T. P.; Dengel, D. R.; Leon, A. S.; Schmitz, K. H. Changes in inflammatory biomarkers following one-year of moderate resistance training in overweight women. Int. J. Obes. 2007, 31, 996-1003.
48. Badawi, A.; Klip, A.; Haddad, P.; Cole, D. E. C.; Bailo, B. G.; El-Sohemy, A.; Karmali, M. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab. Syndr. Obes. 2010, 26, 173-186.
49. Christiansen, T.; Paulsen, S. K.; Bruun, J. M.; Pedersen, S. B. Richelsen, B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: A 12-week randomized intervention study. Am. J. Physiol. Endocrinol. Metab. 2010, 298, E824-E831.
50. Rosenzweig, J. L.; Ferrannini, E.; Grundy, S. M.; Haffner, S. M.; Heine, R. J.; Horton, E. S.; Kawamori, R. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008, 93, 3671-3689.
51. Lalic, N. M.; Zamaklar, M.; Pudar, G. Early Detection and Prevention of Type 2 Diabetes: National Program Serbia. In Diabetes Prevention in Practice, ISBN 978-3-00-030765-2; Schwarz, P., Reddy, P., Greaves, C., Dunbar, J., Schwarz, J., Eds.; TUMAINI Institute for Prevention Management: Dresden, Germany, 2010; pp. 117-124.